Driving the next generation of disease-modifying therapies for Parkinson’s and other complex neurodegenerative disorders.
Brenig Therapeutics is a biotechnology company pioneering the development of innovative small-molecule therapies for neurodegenerative diseases. Leveraging decades of drug development expertise and cutting-edge research enhanced by AI and machine learning, we are committed to delivering disease-modifying treatments that target the root causes of debilitating neurological conditions.
Pipeline
BT-267: Targeting LRRK2-Driven Lysosomal Pathology
BT-267 is a selective, brain-penetrant small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2)—a key protein implicated in the pathogenesis of Parkinson’s disease. Designed to maximize CNS exposure while minimizing peripheral activity, BT-267 offers a differentiated profile aimed at reducing off-target and systemic side effects.
Engineered for optimal selectivity, pharmacokinetics and pharmacodynamics, BT-267 has demonstrated best-in-class potential in preclinical and clinical studies, showing high brain penetration, minimal peripheral exposure, and a favorable safety and tolerability profile.
Mutations in LRRK2 represent one of the most common genetic causes of Parkinson’s disease, and dysregulated LRRK2 activity is associated with lysosomal and mitochondrial dysfunction. By precisely targeting this pathway, BT-267 may offer a disease-modifying approach to slowing—or potentially halting—the progression of Parkinson’s and related neurodegenerative conditions.
BT-409: Targeting NLRP3-Driven Neuroinflammation
BT-409 is a highly selective, CNS-penetrant small-molecule inhibitor of the NLRP3 inflammasome, developed as a potential best-in-class therapy for Parkinson’s disease. Designed to deliver effective brain-specific NLRP3 inhibition while minimizing on- and off-target effects, BT-409 has demonstrated a promising safety and pharmacokinetic profile in preclinical neuroinflammation models.
In addition to Parkinson’s, BT-409 may have broad therapeutic potential across other neuroinflammatory conditions, including multiple sclerosis (MS), Alzheimer’s disease, and stroke. We plan to advance BT-409 into Phase 1 safety studies in 2025.
The NLRP3 inflammasome plays a critical role in innate immunity by clearing pathogens and damaged cells. However, chronic activation leads to sustained release of pro-inflammatory cytokines, triggering neuroinflammation that contributes to neuronal damage and disease progression. Elevated NLRP3 activity has been observed in patients with Parkinson’s disease and correlates with disease severity, making it a compelling target for disease-modifying intervention.
About Us
Brenig Therapeutics was co-founded in 2021 by OrbiMed, Torrey Pines, and BGV to design and develop breakthrough medicines for neurodegenerative disorders. Brenig’s mission is to build a robust portfolio of first- and best-in-class therapies targeting a broad spectrum of neurodegenerative diseases, starting with Parkinson’s disease.
Our lead program is a potential best in class LRRK2 inhibitor developed using advanced AI-driven drug discovery models. This pioneering approach enabled the creation of a highly selective, brain-penetrant molecule that has rapidly progressed from discovery into clinical development.
Our Investors
